Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery
This trial is active, not recruiting.
|Treatments||celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin|
|Sponsor||Alliance for Clinical Trials in Oncology|
|Collaborator||National Cancer Institute (NCI)|
|Start date||June 2010|
|End date||December 2019|
|Trial size||2500 participants|
|Trial identifier||NCT01150045, CALGB-80702, CDR0000675693, U10CA031946|
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer.
|United States||Indiana, Kansas, and Maryland|
|Other countries||No locations recruiting|